

Supplementary Materials

Table S1. Total irAEs divided by type and tumor.

irAEs	Total (n.196)	mRCC (n.63)	mM (n. 70)	mNSCLC (n. 63)
<i>Endocrine</i>	38 (22,6%)	20 (46,5%)	7 (11,5%)	11 (17,2%)
G1-G2	35 (20.8%)	19 (44.2%)	5 (8.2%)	11 (17.2%)
G3-G4	3 (1.8%)	1 (2.3%)	2 (3.3%)	0 (0%)
<i>Hepato-gastrointestinal</i>	43 (25.6%)	12 (27.9%)	17 (27.9%)	14 (21.9%)
G1-G2	37 (22.0%)	7 (16.3%)	16 (26.2%)	14 (21.9%)
G3-G4	6 (3.6%)	5 (11.6%)	1 (1.6%)	0 (0%)
<i>Dermatological</i>	33 (19.6%)	10 (23.3%)	13 (21.3%)	10 (15.6%)
G1-G2	32 (19.0%)	10 (23.3%)	13 (21.3%)	9 (14.1%)
G3-G4	1 (0.6%)	0 (0%)	0 (0%)	1 (1.6%)
<i>Rheumatological</i>	15 (8.9%)	4 (9.3%)	5 (8.2%)	6 (9.4%)
G1-G2	14 (8.3%)	3 (7.0%)	5 (8.2%)	6 (9.4%)
G3-G4	1 (0.6%)	1 (2.3%)	0 (0%)	0 (0%)
<i>Pulmonary</i>	18 (10.7%)	5 (11.6%)	7 (11.5%)	6 (9.4%)
G1-G2	13 (7.7%)	3 (7.0%)	4 (6.6%)	6 (9.4%)
G3-G4	5 (3.0%)	2 (4.7%)	3 (4.9%)	0 (0%)
<i>Others</i>	49 (29.2%)	12 (27.9%)	21 (34.4%)	16 (25.0%)
G1-G2	44 (26.2%)	11 (27.9%)	17 (27.9%)	16 (25.0%)
G3-G4	5 (3.0%)	1 (2.3%)	4 (6.6%)	0 (0%)